Table 4 Multivariable Cox regression analyses predicting cancer-specific survival
All stage | T1 | T2 | T3 | T4 | |
|---|---|---|---|---|---|
Multivariable a HR (95% CI) | Multivariable b HR (95% CI) | Multivariable b HR (95% CI) | Multivariable b HR (95% CI) | Multivariable b HR (95% CI) | |
LND status | |||||
No LND | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) |
LND | 0.81 (0.73–0.95)** | 0.84 (0.56–1.25) | 0.87 (0.61–1.24) | 0.83 (0.73–0.98)* | 0.64 (0.47–0.88)** |
LND extent | |||||
No LND | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) |
Limited LND | 0.86 (0.75–0.96)* | 1.02 (0.65–1.59) | 1.02 (0.69–1.51) | 0.92 (0.78–1.16) | 0.61 (0.43–0.87)** |
Extended LND | 0.73 (0.61–0.88)** | 0.56 (0.29–1.08) | 0.65 (0.38–1.12) | 0.74 (0.58–0.95)* | 0.70 (0.47–0.96)* |
Lymph node stage | |||||
pN0 | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) | 1.00 (Ref.) |
pNx | 1.32 (1.13–1.53)*** | 1.29 (0.85–1.98) | 1.19 (0.83–1.72) | 1.22 (1.01–1.49)* | 1.97 (1.31–2.97)** |
pN1–3 | 2.49 (2.06–3.01)*** | 3.40 (1.61–7.18)** | 3.35 (1.87–5.99)*** | 2.32 (1.81–2.98)*** | 2.55 (1.64–3.98)*** |